Kevin Patrick Danahy Sells 20,000 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) insider Kevin Patrick Danahy sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $21.45, for a total value of $429,000.00. Following the completion of the transaction, the insider owned 43,298 shares of the company’s stock, valued at approximately $928,742.10. The trade was a 31.60% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kevin Patrick Danahy also recently made the following trade(s):

• On Wednesday, February 11th, Kevin Patrick Danahy sold 20,000 shares of Pulse Biosciences stock. The stock was sold at an average price of $25.20, for a total value of $504,000.00.

Pulse Biosciences Trading Up 5.6%

PLSE traded up $1.33 during trading on Wednesday, reaching $25.25. The stock had a trading volume of 466,845 shares, compared to its average volume of 386,842. The company has a market capitalization of $1.71 billion, a price-to-earnings ratio of -22.35 and a beta of 1.77. The stock’s 50 day moving average is $14.97 and its two-hundred day moving average is $15.66. Pulse Biosciences, Inc has a one year low of $12.56 and a one year high of $26.30.

Analyst Ratings Changes

PLSE has been the topic of several research reports. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a research note on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Thursday, January 22nd. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Pulse Biosciences presently has an average rating of “Hold” and a consensus target price of $26.00.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets boosted its holdings in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock valued at $26,000 after acquiring an additional 680 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Pulse Biosciences by 275.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after purchasing an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. grew its position in Pulse Biosciences by 44.0% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after purchasing an additional 1,372 shares during the period. KLP Kapitalforvaltning AS raised its stake in Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock valued at $104,000 after buying an additional 3,400 shares during the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Pulse Biosciences by 184.5% during the 2nd quarter. AlphaQuest LLC now owns 8,864 shares of the company’s stock valued at $134,000 after buying an additional 5,748 shares during the period. 76.95% of the stock is owned by hedge funds and other institutional investors.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.